← All indications
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
Subtype terms (9)
More specific conditions that are subtypes of Hypertension in the MeSH hierarchy.
- Essential Hypertension
113 drugs (63 approved, 50 experimental)
- Hypertension, Malignant
- Hypertension, Pregnancy-Induced
32 drugs (27 approved, 5 experimental)
- Hypertension, Pulmonary
173 drugs (110 approved, 63 experimental)
- Hypertension, Renal
9 drugs (5 approved, 4 experimental)
- Hypertensive Crisis
- Hypertensive Retinopathy
- Masked Hypertension
7 drugs (4 approved, 3 experimental)
- White Coat Hypertension
1 drug approved
Drugs by status
Approved for this indication (136)
- bendroflumethiazide
- guanabenz
- benazepril
- mecamylamine
- arotinolol
- protein hydrolysates
- azelnidipine
- indapamide
- nicardipine
- tianmagouteng
- hydroflumethiazide
- felodipine
- aprocitentan
- carvedilol
- chlorothiazide
- minoxidil
- rilmenidine
- alkavervir
- lercanidipine
- trifluoromethylthiazide
- vitamin e
- moexipril
- candesartan
- Ocedurenone
- manidipine
- nadolol
- lacidipine
- sodium mersalyl
- metoprolol
- triamterene
- +106 more
Phase 4 trials (110)
- tranexamic acid
- ramelteon
- remifentanil
- fluvastatin
- icosapent ethyl
- sevoflurane
- levobupivacaine
- enoxaparin
- suvorexant
- substance p
- calcium
- sildenafil
- olive
- sibutramine
- digoxin immune fab (ovine)
- nesiritide
- estradiol
- sirolimus
- glucose
- magnesium citrate
- soybean oil
- empagliflozin
- folic acid
- Silibinin
- fentanyl
- Bunazosin
- warfarin
- rosuvastatin
- lidocaine
- enzalutamide
- +80 more
Phase 3 trials (76)
- menthol
- dexamethasone
- bupivacaine
- insulin lispro
- blueberry
- black soy peptide
- annona muricata
- tca108
- darusentan
- prm-125
- qianyangyuyin
- pasireotide
- arginine
- ilepatril
- ethanol
- propofol
- medroxyprogesterone
- ginseng
- ly3502970
- lorundrostat
- linagliptin
- ckd-386
- malic acid
- melissa officinalis
- eculizumab
- esaxerenone
- ruxolitinib
- vasopressin
- drospirenone
- etomidate
- +46 more
Phase 2 trials (90)
Phase 1 trials (93)
- fluticasone
- zma001 (bc-nka-20008)
- ckd-348
- naproxen
- zamicastat
- sal0140
- dibotermin alpha
- besylsartan
- egg
- etamicastat
- ranitidine
- tibolone
- simeprevir
- Mirodenafil
- phentermine
- mk-8150
- ad2072
- ad-227
- cannabidiol
- sodium butyrate
- moxifloxacin
- yohimbine
- darbepoetin alfa
- ckd-320
- pyruvate
- corticotropin
- anastrozole
- ckd-341
- cyanocobalamin
- br101801
- +63 more
Other trials (132)
- mgf-4
- protoveratrine b
- aronia extract
- dopamine
- betahistine mesilate
- proline
- tea
- bevacizumab
- almond
- quercetin
- soybean
- tetraethylammonium
- potassium nitrate
- e
- saccharin
- apple
- peanut
- royal jelly
- butylphthalide
- sodium phosphate
- cevadine
- lactobacillus casei
- sodium nitrate
- dobutamine
- tamarindus
- pomegranate
- salsalate
- butyphthalide
- glucagon-like peptide-1
- vivomixx
- +102 more
Organizations
Organization Involved with Phase 4 Indications (464)
- Govt Medical College, Bhavnagar
- State University of New York
- Inje University
- University of Ulsan
- Damanhour University
- St.-Josefs-Hospital Cloppenburg
- University of Parma
- Monash University
- Chinese Academy of Medical Sciences
- Seoul University
- University of Glasgow
- United Therapeutics
- Daegu Catholic University
- Department of Veteran Affairs
- Centre d'Atenció Primaria Bon Pastor
- Merck Serono
- University of Paris
- Hospital Universitario Central de Asturias
- Cornell University
- Bayer
- Skaraborg Hospital
- Centro de Salud de Fuentealbilla, Fuentealbilla, Albacete, Spain
- OSCAR Study
- Government of China
- Otsuka
- Ghent University
- Japan Seamen's Relief Association Moji Hospital
- Government of Finland
- University of Campinas
- Kerckoff clinic, Bad Nauheim, Germany
- +434 more
Organization Involved with Phase 3 Indications (228)
- University of California, Davis
- CJ HealthCare Corp.
- Laboratorios Sophia S.A de C.V.
- Centro de Investigación en Alimentación y Desarrollo A.C.
- Washington University in St. Louis
- Moscow State University
- Fujian Medical University
- Aventis
- Justus Liebig University Giessen
- University of Texas, Galveston
- Adapt Produtos Oftalmológicos Ltda.
- Perrigo
- University Mulitiprofile Hospital for Active Treatment Sv.Georgi, Bulgaria
- University of Tuebingen
- Covance
- Ontario Ginseng Growers Association
- Ain Shams University
- Quantum Genomics SA
- Liaoning Hospital of Traditional Chinese Medicine
- Effi-stat
- Hamilton Health Sciences Corporation
- CORDA, The Heart Charity
- Stendhal Americas, S.A.
- University of Milan
- Dong-A University
- DEOEC Institute of Cardiology
- Hanyang University
- Lifecenter Hospital
- Shields, Shields and Associates
- Chung-Ang University
- +198 more
Organization Involved with Phase 2 Indications (189)
- Advent Health
- IKP Bobenheim GmbH
- Centro de la Salud de Vistalegre - La Flota, Murcia (Spain)
- Sohag University
- University of Minnesota
- Henry Ford Health System
- Navitas Pharma
- CinCor Pharma, Inc.
- The Korean Society of Ginseng
- Michigan State University
- Government of Scotland
- Precision Medicine
- Florida State University
- FGK Clinical Research GmbH
- Hospital General Dr. Manuel Gea Gonzalez
- Medfiles
- RMJ Holdings, LLC
- National Institute of Allergy and Infectious Diseases (NIAID)
- CoTherix
- Serodus ASA
- Shin Poong Pharmaceuticals
- MicroConstants
- Philips
- Speedel Pharma Ltd.
- St. Jude Children's Hospital
- Bracco
- Shanghai Pharmaceuticals Holding Co., Ltd
- Biomarin
- Relypsa
- National Autonomous University of Mexico
- +159 more
Organization Involved with Phase 1 Indications (63)
- Shahid Beheshti University of Medical Sciences
- Fayoum University
- Masih Daneshvari Hospital
- PRACS
- Yiling Pharmaceutical Inc.
- MannKind Corp
- PharmaNet (2006)
- University of Oklahoma
- Augusta University
- University of Virginia
- SRI International
- Changi General Hospital
- Ng Teng Fong General Hospital
- Hospital Carlos Fernando Malzoni
- National University of Singapore
- Anam Hospital
- Prism Research
- Norwegian Military
- Alnylam Pharmaceuticals
- Orlando Clinical Research Center
- North Carolina A&T State Univeristy
- PharmaKinetics Laboratories Inc.
- Spaulding Clinical Research Inc.
- Dr. Ruth K.M. Pfau Civil Hospital, Karachi
- OpAns, LLC
- University of Cologne
- Eye Therapies, LLC
- New Orleans Center for Clinical Research
- California Institute for Regenerative Medicine
- Gmax Biopharm Australia Pty Ltd.
- +33 more
Organization Involved with Other Experimental Indications (119)
- The S. Daniel Abraham International Center for Health and Nutrition
- Amgen
- BioTeSys GmbH
- ZNA Antwerpen
- Long Beach Memorial Medical Center
- Beneo GmbH
- Beijing Hypertension League Insititute
- Unilever
- University of California, Irvine
- Martin Luther University
- Gsap Medical Ltd.
- Northumbria University
- The Rogosin Institute
- Shanxi Kangbao Pharmaceutical company
- Humboldt University
- University of Colorado
- Nippon Shinyaku Co Ltd
- LycoRed Ltd.
- The Louis & Rachel Rudin Foundation
- Sao Paulo State University
- Massey University
- Dr. Loges & Co. GmbH
- QMUL
- Marywood University
- Stem Medicina Regenerativa
- Xingtai People's Hospital
- Scios
- University of Leeds
- Fruitura Bioscience Ltd.
- Chung Shan Medical University
- +89 more